The board of directors of Shanghai Junshi Biosciences Co., Ltd. announced that the company's product Toripalimab Injection (trade name: TUOYI) and Deuremidevir Hydrobromide Tablets (trade name: MINDEWEI) were successfully included in Category B of the National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (Year 2023) (the NRDL) upon negotiations. In particular, TUOYI has 3 new indications included, all six approved indications of TUOYI in China are included in the NRDL currently, and TUOYI is the only anti-PD-1 monoclonal antibody included in the NRDL for the treatment of melanoma. The indication of MINDEWEI for adult patients with mild to moderate coronavirus disease 2019 (COVID-19) is officially included in the NRDL for the first time.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.74 HKD | +4.88% | +16.23% | -44.75% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-44.75% | 3.18B | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.35B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- 1877 Stock
- News Shanghai Junshi Biosciences Co., Ltd.
- Shanghai Junshi Biosciences Co., Ltd. Announces New Indications of TUOYI and MINDEWEI Included in New Edition of National Reimbursement Drug List